Debut Of Merck's Anacetrapib Debut Many Years Away, Despite Robust Phase III Data
This article was originally published in The Pink Sheet Daily
Executive Summary
Filing will wait until after 2015, pending results of a soon-to-launch CV outcomes study of the CETP inhibitor in 30,000 patients.
You may also be interested in...
Dalcetrapib Failure Raises Yet More Questions On Value Of Tinkering With HDL Cholesterol
Termination of the development program for dalcetrapib creates more doubt about the class of CETP inhibitors, long viewed with ambivalence. But important differences in how the drug works compared to rivals leaves room for some to hold out hope for CETP inhibition and the HDL hypothesis in general.
Resverlogix Plays Up Importance Of New Study After Missing Phase II Endpoint
Resverlogix Corp. says it is keeping its faith in RVX-208 – a cholesterol drug designed to improve HDL function – despite missing a primary efficacy endpoint in the Phase II ASSERT trial, facing questions over a newly seen liver signal, and suffering a major blow to its stock price.
Resverlogix Plays Up Importance Of New Study After Missing Phase II Endpoint
Resverlogix Corp. says it is keeping its faith in RVX-208 – a cholesterol drug designed to improve HDL function – despite missing a primary efficacy endpoint in the Phase II ASSERT trial, facing questions over a newly seen liver signal, and suffering a major blow to its stock price.